LETROZOL Amarox 2,5 mg Filmtabletten

Description

Indications

Early-stage invasive breast cancer, whose cells have hormone receptors, in postmenopausal women as adjuvant therapy.
Early stage invasive breast cancer in postmenopausal women after completion of standard adjuvant therapy with tamoxifen for 5 years as prolonged adjuvant therapy.
Disseminated hormone-dependent breast cancer in postmenopausal women (first-line therapy).
Disseminated breast cancer with disease recurrence or progression in postmenopausal women (natural or artificially induced) who have received prior anti-estrogen therapy. – Hormone-dependent HER-2 negative breast cancer in postmenopausal women as neoadjuvant therapy when chemotherapy is contraindicated and emergency surgery is not required.

Method of use

Intravenously, irrespective of meals.
Adults: the recommended dose of Letrozole is 2.5 mg once daily, daily, long-term (for 5 years or until relapse).
As part of extended adjuvant therapy, treatment should be continued for 4 years (not more than 5 years).
Letrozole should be discontinued if there are signs of disease progression.
In patients with end-stage disease or metastatic cancer, treatment with letrozole should be continued as long as tumour progression is apparent).
No dose adjustment of letrozole is required in elderly patients.
Patients with hepatic and/or renal impairment: no dose adjustment is required for hepatic or renal impairment (creatinine clearance >10 ml/min). However, in cases of severe hepatic impairment (Child-Pugh class C), patients should be under constant observation.